SymphonyAI Industrial Launches Batch 360™ and Vision 360™ for high-quality manufacturing production September 6, 2022 6:30 am|AI-based software delivers actionable insights for manufacturers to optimize and maintain production output quality
California facing chance of blackouts amid brutal heat wave September 6, 2022 6:27 am|LOS ANGELES (AP) — California will face its highest chance of blackouts this year as a brutal heat…
iQIYI Further Upgrades Online Film Distribution Model to Increase Revenue for Film Producers, Driving Industry Growth September 6, 2022 6:13 am|BEIJING, Sept. 6, 2022 /PRNewswire/ — iQIYI, an innovative market-leading online entertainment service in China, announced recently that it…
LightInTheBox Reports Second Quarter 2022 Financial Results September 6, 2022 6:12 am|SHANGHAI, Sept. 6, 2022 /PRNewswire/ — LightInTheBox Holding Co., Ltd. (NYSE: LITB) (“LightInTheBox” or the “Company”), a cross-border e-commerce…
Henderson Engineers and Torch.AI Test New AI for Building Systems Design September 6, 2022 6:03 am|LEAWOOD, Kan., Sept. 6, 2022 /PRNewswire/ — Torch.AI, pioneers of Data Infrastructure AI™, is testing a new artificial…
‘Really shocked’: Beachgoer prays for woman bitten by shark September 6, 2022 6:00 am|HONOLULU (KHNL/Gray News) – A Hawaii visitor was hospitalized in critical condition after she was bitten by a…
IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma September 6, 2022 6:00 am|– Investigator Sponsored Trial sites in Australia include St. Vincent’s Hospital, Sydney, Alfred Health, Melbourne, and the Royal…
ScriptSender Streamlines Referrals and Prior Authorizations at Chesapeake Medical Imaging September 6, 2022 6:00 am|Fast implementation enables dramatic increase in referrer integration and loyalty.
BOOHOO ANNOUNCES AMBASSADOR KOURTNEY KARDASHIAN BARKER September 6, 2022 6:00 am|KOURTNEY KARDASHIAN BARKER COLLABORATES WITH BOOHOO TO DISCOVER MORE ABOUT SUSTAINABILITY & STYLE. WORKING TO EMPOWER HERSELF AND…
Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis) September 6, 2022 6:00 am|LA JOLLA, Calif., Sept. 6, 2022 /PRNewswire/ — Helixmith announced topline results today from a Phase 2A study…